Obinutuzumab


Indications and Reactions:

Role Indications Reactions
Primary
Diffuse Large B-cell Lymphoma 41.2%
Hypertension 6.9%
B-cell Lymphoma 5.9%
Constipation 4.9%
Premedication 4.9%
Prophylaxis 4.9%
Diabetes Mellitus 3.9%
Malnutrition 3.9%
Tuberculosis 3.9%
Chronic Obstructive Pulmonary Disease 2.9%
Abdominal Pain 2.0%
Anaemia 2.0%
Coronary Artery Bypass 2.0%
Hypercholesterolaemia 2.0%
Nausea 2.0%
Neutropenia 2.0%
Oedema 2.0%
Anxiety 1.0%
Arteriosclerosis 1.0%
Bone Pain 1.0%
Febrile Neutropenia 18.2%
Abdominal Pain 9.1%
Colitis 9.1%
Iiird Nerve Paralysis 9.1%
Lung Adenocarcinoma 9.1%
Mucosal Inflammation 9.1%
Rash Maculo-papular 9.1%
Sinus Bradycardia 9.1%
Subileus 9.1%
Upper Gastrointestinal Haemorrhage 9.1%
Secondary
B-cell Lymphoma 48.9%
Diffuse Large B-cell Lymphoma 9.2%
Product Used For Unknown Indication 6.3%
Nausea 3.7%
Non-hodgkin's Lymphoma 3.6%
Pain 3.6%
Infection 3.3%
Prophylaxis 3.0%
Diabetes Mellitus 2.7%
Chronic Lymphocytic Leukaemia 1.8%
Premedication 1.8%
Hypertension 1.7%
Anaemia 1.5%
Anxiety 1.5%
Blood Potassium Decreased 1.5%
Constipation 1.3%
Pyrexia 1.3%
Hypercholesterolaemia 1.2%
Neutropenia 1.2%
Non-hodgkin's Lymphoma Unspecified Histology Indolent 1.2%
Infusion Related Reaction 51.0%
Infection 10.9%
Pyrexia 4.8%
White Blood Cell Count Decreased 4.1%
Respiratory Failure 3.4%
Upper Gastrointestinal Haemorrhage 3.4%
Neutropenia 2.7%
Sepsis 2.7%
Myocardial Infarction 2.0%
Neutropenic Sepsis 2.0%
Pneumonia 2.0%
Tumour Lysis Syndrome 2.0%
Febrile Neutropenia 1.4%
Multi-organ Failure 1.4%
Pancytopenia 1.4%
Pneumonitis 1.4%
Sinus Bradycardia 1.4%
Bronchopneumonia 0.7%
Diarrhoea 0.7%
Eastern Cooperative Oncology Group Performance Status Worsened 0.7%

Drug Data